Whitehawk Therapeutics (WHWK) Equity Average: 2018-2025
Historic Equity Average for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to $164.6 million.
- Whitehawk Therapeutics' Equity Average rose 122.97% to $164.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.6 million, marking a year-over-year increase of 122.97%. This contributed to the annual value of $78.8 million for FY2024, which is 40.18% down from last year.
- Latest data reveals that Whitehawk Therapeutics reported Equity Average of $164.6 million as of Q3 2025, which was down 16.39% from $196.9 million recorded in Q2 2025.
- Whitehawk Therapeutics' Equity Average's 5-year high stood at $196.9 million during Q2 2025, with a 5-year trough of $13.3 million in Q1 2021.
- Its 3-year average for Equity Average is $122.1 million, with a median of $124.8 million in 2023.
- Per our database at Business Quant, Whitehawk Therapeutics' Equity Average crashed by 61.75% in 2021 and then surged by 881.32% in 2022.
- Over the past 5 years, Whitehawk Therapeutics' Equity Average (Quarterly) stood at $143.7 million in 2021, then climbed by 13.98% to $163.7 million in 2022, then crashed by 31.79% to $111.7 million in 2023, then plummeted by 45.68% to $60.7 million in 2024, then surged by 122.97% to $164.6 million in 2025.
- Its last three reported values are $164.6 million in Q3 2025, $196.9 million for Q2 2025, and $137.1 million during Q1 2025.